Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL350386

CC(C)CC(C)CCCO.O=C(O)C(F)(F)F

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
BLM P54132 1/20 0.36
ATR Q13535 1/20 0.35
GRN P28799 1/20 0.34
SORT1 Q99523 1/20 0.34
RNPEP Q9H4A4 1/20 0.32
SLC7A5 Q01650 1/20 0.32
CTSS P25774 2/20 0.31
CTSK P43235 2/20 0.31
CTSL P07711 1/20 0.31
DPP8 Q6V1X1 1/20 0.31
DPP7 Q9UHL4 1/20 0.31
MLYCD O95822 1/20 0.31
ACE2 Q9BYF1 1/20 0.31
TRPA1 O75762 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13667174 0.82 LMNA (0.39) BLMTRPA1
SCHEMBL1052619 0.82 LMNA (0.39) BLMTRPA1
Trifluoroacetic Acid SCHEMBL720969 0.81 ACE2 (0.46) BLMACE2
Trifluoroacetic Acid SCHEMBL3918426 0.80 ACE2 (0.53) MLYCDACE2
SCHEMBL11429360 0.78 LMNA (0.36) BLMTRPA1
Trifluoroacetic Acid SCHEMBL12497790 0.77 ACE2 (0.42) DPP8DPP7ACE2
Trifluoroacetic Acid SCHEMBL349303 0.77 KDM4C (0.39) BLMATRACE2
SCHEMBL1657981 0.75 LMNA (0.43) BLMACE2TRPA1
SCHEMBL16832065 0.75 BLM (0.39) BLMRNPEPSLC7A5ACE2
SCHEMBL1657739 0.73 LMNA (0.42) BLMACE2TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8647882-B2 Chiral selectors and stationary phases for separating enantiomer mixtures EVONIK DEGUSSA GMBH (DE) 2014-02-11 US disclosed
US-8268631-B2 Chiral selectors and stationary phases for separating enantiomer mixtures EVONIK DEGUSSA GMBH (DE) 2012-09-18 US disclosed
US-20120015443-A1 NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES EVONIK DEGUSSA GMBH (DE) 2012-01-19 US disclosed
US-20090229352-A1 NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES EVONIK DEGUSSA GMBH (DE) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015443-A1 NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES BCAT2, BCAT1, SLC43A1 BLM 3624/4885ATR 1234/4885GRN 4582/4885
US-20090229352-A1 NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES BCAT2, BCAT1, SLC43A1 BLM 3624/4885ATR 1234/4885GRN 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.